Certificate of Analysis

Thaw and Culture Details

Cell Line Name	**SCRP2706i**	
WiCell Lot Number	**DB42864**	
Provider/Client	The Scripps Research Institute – Laboratory of Dr. Eric Topol	
Banked By	Gladstone Institutes – Laboratory of Dr. Sheng Ding	
Thaw and Culture Recommendations	WiCell recommends thawing 1 vial into 3 wells of a 6 well plate using mTeSR™1 and Matrigel®. WiCell recommends thawing using ROCK Inhibitor for best results.	
Protocol	WiCell Feeder Independent Pluripotent Stem Cell Protocol	
Culture Platform Prior to Freeze	Medium: mTeSR™1	Matrix: Matrigel®
Passage Number	p10 Cells were cultured for 10 passages prior to freeze and post colony selection. Plated cells at thaw should be labeled passage 11.	
Date Vialed	26-MAY-2016	
Vial Label	C00519, Passage 10, May-26-2016	
Biosafety and Use Information	Appropriate biosafety precautions should be followed when working with these cells. The end user is responsible for ensuring that the cells are handled and stored in an appropriate manner. WiCell is not responsible for damages or injuries that may result from the use of these cells. Cells distributed by WiCell are intended for research purposes only and are not intended for use in humans.	

Certificate of Analysis

Results

Test Description	Test Provider	Test Method	Test Specification	Result
Karyotype	WiCell	G-T-L Banding performed on 20 metaphase cells	Expected karyotype	See Report
	Results: 46,XX ***Interpretation:*** This is a normal karyotype; no clonal abnormalities were detected at the stated band level of resolution.			
Post-Thaw Viable Cell Recovery	WiCell	Thaw using specified Thaw & Culture Recommendations	Recoverable attachment after passage	Pass
Identity by STR	WiCell	PowerPlex 16 HS System by Promega™	Defines STR profile of deposited cell line	See Report
Mycoplasma	WiCell	PCR	Amplification of mycoplasma specific DNA detected with negative result	Pass
Sterility	Steris	Native Product Direct Transfer using FTM and TSB (ST/07)	Negative for growth following 14 days of culture	Pass

Testing Reported by Provider

The Provider stated that some or all of the additional analyses listed below may have been performed for this cell line. For more information, publication and dbGaP links, where available, are provided on the cell line specific web page on the WiCell website.

- HumanCore Exome Kit
- Methylation
- Tra1-60 marker expression via flow cytometry
- Infinium® Expanded Multi-Ethnic Genotyping Array (MEGAEX)

Approval Date	WiCell Quality Assurance Approval
04-March-2025	3/4/2025 X HEB HEB WiCell Quality Assurance Signed by: HBruner

Chromosome Analysis Report: 105682

Date Reported: February 09, 2025
Cell Line: SCRP2706i-DB42864
Submitted Passage #: 14
Date of Sample: 1/31/2025
Specimen: Human IPSC
Results: 46,XX

Cell Line Sex: Female
Reason for Testing: LOT_RELEASE
Investigator: WiCell Stem Cell Bank, WiCell



Cell: 88
Slide: G01
Slide Type: Karyotype

Total Counted: 20
Total Analyzed: 8
Total Karyogrammed: 4
Band Resolution: 450 - 525

Interpretation:
This is a normal karyotype; no clonal abnormalities were detected at the stated band level of resolution.

Completed by: Kate Bird, CG(ASCP)
Reviewed and Interpreted by: Justin Schleede, PhD, FACMG

For internal use only

Date:_____ **Sent By:**____ **Sent To:**_____ **QC Review By:** ____

Limitations: This assay allows for microscopic visualization of numerical and structural chromosome abnormalities. The size of structural abnormality that can be detected is >3-10Mb, dependent upon the G-band resolution obtained from this specimen. For the purposes of this report, band level is defined as the number of G-bands per haploid genome. It is documented here as "band level", i.e., the range of bands determined from the four karyograms in this assay. Detection of heterogeneity of clonal cell populations in this specimen (i.e.,mosaicism) is limited by the number of metaphase cells examined, documented here as "# of cells counted".

Short Tandem Repeat

Requestor: WiCell Stem Cell Bank, WiCell
Sample Receipt Date: 31Jan25, 02Feb25, 03Feb25, 05Feb25
STR Amplification Date: 10Feb25

Sample Name	SCRP2706i-DB42864 p14	WIBR3-S1-WB68685 p36	SCRP9001i-DB43138 p12	SCRP8717i-DB43132 p13
WiCell CTR No.[1]	105682	105684	105736	105805
FGA	[redacted]			
TPOX				
D8S1179				
vWA				
Amelogenin				
Penta_D				
CSF1PO				
D16S539				
D7S820				
D13S317				
D5S818				
Penta_E				
D18S51				
D21S11				
TH01				
D3S1358				
Allelic Polymorphisms	24	28	28	27
Matches[2]				
Comments				

Identifying information has been redacted to protect donor confidentiality. If more information is required, please contact info@wicell.org

[1] CTR No.: Characterization Test Request Number; also known as a laboratory accessioning number.
[2] The STR profile of the sample(s) listed are a 100% match for the given sample unless otherwise specified.

Short Tandem Repeat

Requestor: WiCell Stem Cell Bank, WiCell
Sample Receipt Date: 31Jan25, 02Feb25, 03Feb25, 05Feb25
STR Amplification Date: 10Feb25

Assay Description: Short Tandem Repeat (STR) analysis is performed using the PowerPlex® 16 HS System by Promega™. Results are reported as 13 CODIS STR markers, Amelogenin for sex determination and two low-stutter, highly discriminating pentanucleotide STR markers.

Results: The genotypic profiles comprise a range of 24-28 allelic polymorphisms across the 15 STR loci analyzed.

Interpretation: The concentration of DNA required to achieve an acceptable STR genotype (signal/ noise) was equivalent to that required for the standard procedure (~1 ng/amplification reaction) from human genomic DNA. These results suggest that the cells submitted correspond to the cell lines as named and were not contaminated with any other human cells or a significant amount of mouse feeder layer cells.

Sensitivity: Sensitivity limits for detection of STR polymorphisms unique to either this or other human cell lines is ~2-4%.

2/18/2025 X John Raff Tech #1 Characterization Signed by: Raff, John	2/18/2025 X Amber Kuhn Tech #2 Characterization Signed by: Kuhn, Amber	2/18/2025 X Dawn Graham QA Review Quality Assurance Signed by: Graham, Dawn

Mycoplasma Assay Report

PCR-based assay performed by WiCell
WiCell Stem Cell Bank, WiCell
04Feb25

Form SOP-83.01
Version 6.0

Sample Name	Result	Interpretation
SCRP4301i-DB42912 p15 (105739)	Negative	Band was not seen at 270bp, indicating the absence of mycoplasma.
SCRP2706i-DB42864 p15 (105738)	Negative	Band was not seen at 270bp, indicating the absence of mycoplasma.
SCRP4502i-DB42918 p15 (105708)	Negative	Band was not seen at 270bp, indicating the absence of mycoplasma.
WIBR3-S1-WB68685 p36 (105684)	Negative	Band was not seen at 270bp, indicating the absence of mycoplasma.
Positive (+) Control	Positive	
Negative (-) Control	Negative	

Assay Description
Sample is tested for presence of mycoplasma using EZ-PCR™ Mycoplasma Detection Kit (Sartorius).

2/4/2025 X Steph Dos Santos Tech #1 Characterization Signed by: Dos Santos, Stephany	2/5/2025 X Kaylie Haddix Tech #2 Characterization Signed by: Haddix, Kaylie	2/5/2025 X Dawn Graham QA Review Quality Assurance Signed by: Graham, Dawn

A gel image is available upon request.

Native Product Sterility Report

STERIS

WiCell
504 S Rosa Road, Rm 101
Madison, WI 53719

SAMPLE #: 21040020
DATE RECEIVED: 01-Apr-21
TEST INITIATED: 02-Apr-21
TEST COMPLETED: 16-Apr-21

SAMPLE NAME / DESCRIPTION:
SCRP2102i-WB67635
SCRP0601i-WB67634
MIN25i-35613.SF-1-WB67632
SCRP1602i-DB42726
SCRP1702i-DB42729
SCRP2001i-DB42732
SCRP2306i-DB42857
SCRP2501i-DB42861
SCRP2706i-DB42864
SCRP2801i-DB42870

UNIQUE IDENTIFIER: N/A

TEST RESULTS:

# Tested	# Positives (Growth)	- Control
10	0	2 Negatives

TEST SUMMARY:

# Samples	Media Type	Volume (mL)	Incubation Temperature (° C)	Incubation Duration (Days)
10	TSB	40	20-25	14
10	FTG	40	30-35	14

REFERENCE: Processed according to LAB-003: Sterility Test Procedure
PD #: 000053
TEST METHODOLOGY: USP - Direct Transfer

COMMENTS: NA

REVIEWED BY _____ DATE 16APR2021

Specific test results may not be indicative of the characteristics of any other samples from the same lot or similar lots. This test report shall not be reproduced, except in full, without prior written approval. Liability is limited to the costs of the tests.Results applied to samples as received.